<DOC>
	<DOCNO>NCT00170664</DOCNO>
	<brief_summary>The combination paclitaxel carboplatin three week schedule emerge current standard approach adjuvant treatment ovarian cancer . Based phase I study multi-center phase II-trial conduct .</brief_summary>
	<brief_title>Taxol/ Carboplatin First Line Therapy Patients With Epithelial Ovarian Cancer</brief_title>
	<detailed_description />
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>histologicallyconfirmed epithelial ovarian cancer FIGO stage IIB IV life expectancy three month ECOG performance status le 3 laboratory parameter within normal range , include glomerular filtration rate ( GFR ) great 60 ml/min , serum creatinine level 1.6 mg/dl , liver transaminase less two time normal level , bilirubin concentration 1.5 mg/dl , adequate bone marrow function indicate neutrophil count great 1,500/µl , platelet count great 100,000/µl . write informed consent suffer secondary malignancy underlie serious , uncontrolled concurrent medical psychiatric disease radiotherapy within 4 week study entry</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Ovarian neoplasm</keyword>
	<keyword>paclitaxel , carboplatin</keyword>
	<keyword>clinical trial , phase II</keyword>
	<keyword>first-line chemotherapy</keyword>
	<keyword>weekly therapy schedule</keyword>
</DOC>